Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, 4D Molecular Therapeutics Inc’s stock clocked out at $10.92, up 0.83% from its previous closing price of $10.83. In other words, the price has increased by $0.83 from its previous closing price. On the day, 0.56 million shares were traded. FDMT stock price reached its highest trading level at $11.11 during the session, while it also had its lowest trading level at $10.64.
Ratios:
To gain a deeper understanding of FDMT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.42 and its Current Ratio is at 8.42. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.04.
On January 13, 2025, BMO Capital Markets Downgraded its rating to Market Perform which previously was Outperform and also lowered its target price recommendation from $40 to $15. On November 21, 2024, Morgan Stanley started tracking the stock assigning a Underweight rating and target price of $8.Morgan Stanley initiated its Underweight rating on November 21, 2024, with a $8 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 17 ’25 when Bizily Scott sold 1,635 shares for $10.59 per share. The transaction valued at 17,315 led to the insider holds 3,594 shares of the business.
SCOTT BIZILY bought 1,635 shares of FDMT for $17,642 on Nov 17 ’25. On Oct 24 ’25, another insider, Bizily Scott, who serves as the Chief Legal Officer of the company, sold 2,678 shares for $12.00 each. As a result, the insider received 32,136 and left with 3,594 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FDMT now has a Market Capitalization of 623915008 and an Enterprise Value of 341115008. For the stock, the TTM Price-to-Sale (P/S) ratio is 5199.27 while its Price-to-Book (P/B) ratio in mrq is 1.38. Its current Enterprise Value per Revenue stands at 2842.625 whereas that against EBITDA is -1.532.
Stock Price History:
The Beta on a monthly basis for FDMT is 2.95, which has changed by 0.67999995 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, FDMT has reached a high of $12.34, while it has fallen to a 52-week low of $2.23. The 50-Day Moving Average of the stock is 3.97%, while the 200-Day Moving Average is calculated to be 78.20%.
Shares Statistics:
It appears that FDMT traded 840.63K shares on average per day over the past three months and 776990 shares per day over the past ten days. A total of 57.14M shares are outstanding, with a floating share count of 52.02M. Insiders hold about 10.95% of the company’s shares, while institutions hold 65.78% stake in the company. Shares short for FDMT as of 1764288000 were 5049284 with a Short Ratio of 6.01, compared to 1761868800 on 4271739. Therefore, it implies a Short% of Shares Outstanding of 5049284 and a Short% of Float of 9.13.
Earnings Estimates
The performance of 4D Molecular Therapeutics Inc (FDMT) in the stock market is under the watchful eye of 10.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.93, with high estimates of -$0.82 and low estimates of -$1.05.
Analysts are recommending an EPS of between -$2.14 and -$3.9 for the fiscal current year, implying an average EPS of -$3.26. EPS for the following year is -$3.48, with 9.0 analysts recommending between -$2.6 and -$4.3.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $5.34M. There is a high estimate of $8M for the next quarter, whereas the lowest estimate is $25k.
A total of 8 analysts have provided revenue estimates for FDMT’s current fiscal year. The highest revenue estimate was $85.12M, while the lowest revenue estimate was $204k, resulting in an average revenue estimate of $37.74M. In the same quarter a year ago, actual revenue was $37kBased on 6 analysts’ estimates, the company’s revenue will be $22.58M in the next fiscal year. The high estimate is $51.3M and the low estimate is $100k.
